Variant ID: 3-178936082-G-A

NM_006218.2(PIK3CA):c.1624G>A;(p.Glu542Lys)

This variant was identified in 1022 publications




Publications:


Activating PIK3CA mutation promotes adipogenesis of adipose-derived stem cells in macrodactyly via up-regulation of E2F1.

Cell Death & Disease
B Sun, Y Jiang, H Cui, X Fang, G Han, X Dai, S Zhou, H Mao, B Wang
Publication Date: 2020-07-30

Variant appearance in text: PIK3CA: E542K
PMID: 32732866
View BVdb publication page



Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer.

Diagnostics (Basel, Switzerland)
A Niwinska, A Bałabas, M Kulecka, A Kluska, M Piątkowska, A Paziewska, K Pyśniak, W Olszewski, M Mikula, J Ostrowski
Publication Date: 2020-07-28

Variant appearance in text: PIK3CA: Glu542Lys
PMID: 32731384
View BVdb publication page



A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors.

Cancer Cell International
Z Chen, C Chen, T Zhou, C Duan, Q Wang, X Zhou, X Zhang, F Wu, Y Hua, F Lin
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32714096
View BVdb publication page



Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.

Oncology Reports
H Tsuchihashi, T Naruse, S Yanamoto, K Okuyama, K Furukawa, K Omori, M Umeda
Publication Date: 2020-09

Variant appearance in text: PIK3CA: E542K
PMID: 32705230
View BVdb publication page



Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma.

Plos One
P Gunerka, K Gala, M Banach, J Dominowski, J Hucz-Kalitowska, K Mulewski, A Hajnal, EG Mikus, D Smuga, M Zagozda, K Dubiel, J Pieczykolan, BM Zygmunt, M Wieczorek
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32702053
View BVdb publication page



Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.

Therapeutic Advances In Medical Oncology
H Taghizadeh, L Müllauer, RM Mader, M Schindl, GW Prager
Publication Date: 2020

Variant appearance in text: PIK3CA: Glu542Lys
PMID: 32699558
View BVdb publication page



Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors.

Cancers
WA Lai, CY Liu, SY Lin, CC Chen, JF Hang
Publication Date: 2020-07-20

Variant appearance in text: PIK3CA: E542K
PMID: 32698386
View BVdb publication page



Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma.

Acta Neuropathologica Communications
MM Georgescu, MZ Islam, Y Li, ML Circu, J Traylor, CM Notarianni, CN Kline, DK Burns
Publication Date: 2020-07-17

Variant appearance in text: PIK3CA: E542K
PMID: 32680567
View BVdb publication page



A Pilot Study for the Feasibility of Exome-Sequencing in Circulating Tumor Cells Versus Single Metastatic Biopsies in Breast Cancer.

International Journal Of Molecular Sciences
P Kaur, D Campo, TB Porras, A Ring, J Lu, Y Chairez, Y Su, I Kang, JE Lang
Publication Date: 2020-07-08

Variant appearance in text: PIK3CA: E542K
PMID: 32650480
View BVdb publication page



Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.

Neoplasia (New York, N.Y.)
Q Yang, C Zhang, Y Ren, H Yi, T Luo, F Xing, X Bai, L Cui, L Zhu, J Ouyang, P Jiang, W Fan, J Qiu, F Wang, X Xing, Z Zhang, X Zhang, R Zhang
Publication Date: 2020-07-07

Variant appearance in text: PIK3CA: Glu542Lys
PMID: 32650224
View BVdb publication page



Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.

Communications Biology
AL Peille, V Vuaroqueaux, SS Wong, J Ting, K Klinger, B Zeitouni, M Landesfeind, WH Kim, HJ Lee, SH Kong, I Wulur, S Bray, P Bronsert, N Zanella, G Donoho, HK Yang, HH Fiebig, C Reinhard, A Aggarwal
Publication Date: 2020-07-09

Variant appearance in text: PIK3CA: E542K
PMID: 32647357
View BVdb publication page



Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.

Neuro-Oncology Advances
S Portet, R Naoufal, G Tachon, A Simonneau, A Chalant, A Naar, S Milin, B Bataille, L Karayan-Tapon
Publication Date: 2019

Variant appearance in text: PIK3CA: E542K
PMID: 32642646
View BVdb publication page



Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer.

Journal Of Thoracic Disease
B Gini, N Thomas, CM Blakely
Publication Date: 2020-05

Variant appearance in text: PIK3CA: E542K
PMID: 32642201
View BVdb publication page



Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Cancers
S Toomey, J Gunther, A Carr, DC Weksberg, V Thomas, M Salvucci, O Bacon, EM Sherif, J Fay, EW Kay, KM Sheehan, DA McNamara, KL Sanders, G Mathew, OS Breathnach, L Grogan, PG Morris, WC Foo, YN You, JH Prehn, B O'Neill, S Krishnan, BT Hennessy, SJ Furney
Publication Date: 2020-07-06

Variant appearance in text: PIK3CA: E542K
PMID: 32640573
View BVdb publication page



Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.

Breast Cancer Research And Treatment
K Li, N Liao, B Chen, G Zhang, Y Wang, L Guo, G Wei, M Jia, L Wen, C Ren, L Cao, H Mok, C Li, J Lin, X Chen, Z Zhang, T Hou, M Li, J Liu, CM Balch, N Liao
Publication Date: 2020-07-07

Variant appearance in text: PIK3CA: E542K
PMID: 32638235
View BVdb publication page



A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.

International Journal Of Breast Cancer
EJ Anderson, LE Mollon, JL Dean, TL Warholak, A Aizer, EA Platt, DH Tang, LE Davis
Publication Date: 2020

Variant appearance in text: PIK3CA: Glu542Lys
PMID: 32637176
View BVdb publication page



Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy.

Cancers
A Font, M Domènech, R Benítez, M Rava, M Marqués, JL Ramírez, S Pineda, S Domínguez-Rodríguez, JL Gago, J Badal, C Carrato, H López, A Quer, D Castellano, N Malats, FX Real
Publication Date: 2020-07-03

Variant appearance in text: PIK3CA: E542K
PMID: 32635360
View BVdb publication page



Clinical Perspective and Translational Oncology of Liquid Biopsy.

Diagnostics (Basel, Switzerland)
D Fernández-Lázaro, JLG Hernández, AC García, ACD Castillo, MV Hueso, JJ Cruz-Hernández
Publication Date: 2020-06-30

Variant appearance in text: PIK3CA: E542K
PMID: 32629823
View BVdb publication page



Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.

Practical Laboratory Medicine
EB Bernhardt, MD Chamberlin, IP Gorlov, FB de Abreu, KJ Bloch, JD Peterson, GJ Tsongalis, K Shirai, KH Dragnev, TW Miller, LJ Tafe
Publication Date: 2020-08

Variant appearance in text: PI3K: E542K
PMID: 32613070
View BVdb publication page



Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.

Cancer Medicine
JW Lee, DH Lim, KW Sung, HW Cho, HY Ju, JK Hyun, KH Yoo, HH Koo, YL Suh, YS Joung, HJ Shin
Publication Date: 2020-06-30

Variant appearance in text: PIK3CA: E542K
PMID: 32608158
View BVdb publication page



Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations.

Cancers
R Sprissler, B Perkins, L Johnstone, HM Babiker, P Chalasani, B Lau, M Hammer, D Mahadevan
Publication Date: 2020-06-18

Variant appearance in text: PIK3CA: E542K; rs121913273
PMID: 32570879
View BVdb publication page



Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach.

Cancer Informatics
V D'Afonseca, AD Arencibia, A Echeverría-Vega, L Cerpa, JP Cayún, NM Varela, M Salazar, LA Quiñones
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32546937
View BVdb publication page



PIK3CA Mutational Analysis of Parathyroid Adenomas.

Jbmr Plus
A Riccardi, C Lemos, R Ramos, J Bellizzi, K Parham, TC Brown, R Korah, T Carling, J Costa-Guda, A Arnold
Publication Date: 2020-06

Variant appearance in text: PIK3CA: E542K
PMID: 32537547
View BVdb publication page



Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation.

Nature Communications
I Martinez-Corral, Y Zhang, M Petkova, H Ortsäter, S Sjöberg, SD Castillo, P Brouillard, L Libbrecht, D Saur, M Graupera, K Alitalo, L Boon, M Vikkula, T Mäkinen
Publication Date: 2020-06-08

Variant appearance in text: PI3K: E542K
PMID: 32513927
View BVdb publication page



Heterogeneous genomic aberrations in esophageal squamous cell carcinoma: a review.

American Journal Of Translational Research
R Li, P Li, W Xing, H Qiu
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32509161
View BVdb publication page



Clinical significance of PI3K/Akt/mTOR signaling in gastric carcinoma.

International Journal Of Clinical And Experimental Pathology
EJ Jung, JH Suh, WH Kim, HS Kim
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32509071
View BVdb publication page



Multidisciplinary therapy strategy of precision medicine in clinical practice.

Clinical And Translational Medicine
M Qian, Q Li, M Zhang, X Xu, Q Shen, H Chen, X Wang, T Liu, Y Cheng
Publication Date: 2020-01

Variant appearance in text: PIK3CA: E542K
PMID: 32508051
View BVdb publication page



Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.

Cancer Science
K Suda, LA Cruz Diaz, K Yoshihara, H Nakaoka, N Yachida, T Motoyama, I Inoue, T Enomoto
Publication Date: 2020-05-30

Variant appearance in text: PIK3CA: E542K
PMID: 32473611
View BVdb publication page



Detection of ctDNA with Personalized Molecular Barcode NGS and Its Clinical Significance in Patients with Early Breast Cancer.

Translational Oncology
T Yoshinami, N Kagara, D Motooka, S Nakamura, T Miyake, T Tanei, Y Naoi, M Shimoda, K Shimazu, SJ Kim, S Noguchi
Publication Date: 2020-05-27

Variant appearance in text: PIK3CA: E542K
PMID: 32473569
View BVdb publication page



CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.

Jco Precision Oncology
ES Antonarakis, P Isaacsson Velho, W Fu, H Wang, N Agarwal, V Sacristan Santos, BL Maughan, R Pili, N Adra, CN Sternberg, PJ Vlachostergios, ST Tagawa, AH Bryce, AL McNatty, ZR Reichert, R Dreicer, O Sartor, TL Lotan, M Hussain
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32462107
View BVdb publication page



The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis.

Biomed Research International
M Wang, J Li, J Huang, M Luo
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32461963
View BVdb publication page



Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.

Translational Oncology
H Taniguchi, K Uehara, G Nakayama, H Nakayama, T Aiba, N Hattori, M Kataoka, Y Nakano, Y Kawase, O Okochi, H Matsuoka, S Utsunomiya, E Sakamoto, Y Mori, S Umeda, T Shikano, K Komori, M Tajika, S Kadowaki, K Muro, Y Yatabe
Publication Date: 2020-05-16

Variant appearance in text: PIK3CA: E542K
PMID: 32428838
View BVdb publication page



Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma.

Translational Oncology
L Trilla-Fuertes, I Ghanem, J Maurel, L G-Pastrián, M Mendiola, C Peña, R López-Vacas, G Prado-Vázquez, E López-Camacho, A Zapater-Moros, V Heredia, M Cuatrecasas, P García-Alfonso, J Capdevila, C Conill, R García-Carbonero, KE Heath, R Ramos-Ruiz, C Llorens, Á Campos-Barros, A Gámez-Pozo, J Feliu, JÁF Vara
Publication Date: 2020-05-15

Variant appearance in text: N/A
PMID: 32422573
View BVdb publication page



Clinicopathological Characteristics of PIK3CA Mutation and Amplification in Korean Patients with Breast Cancers.

International Journal Of Medical Sciences
MH Lee, JH Cho, SY Kwon, SJ Jung, JH Lee
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32410843
View BVdb publication page



Frequency and spectrum of PIK3CA somatic mutations in breast cancer.

Breast Cancer Research : Bcr
O Martínez-Sáez, N Chic, T Pascual, B Adamo, M Vidal, B González-Farré, E Sanfeliu, F Schettini, B Conte, F Brasó-Maristany, A Rodríguez, D Martínez, P Galván, AB Rodríguez, A Martinez, M Muñoz, A Prat
Publication Date: 2020-05-13

Variant appearance in text: PIK3CA: E542K
PMID: 32404150
View BVdb publication page



Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.

Cells
AA Ghodsinia, JMT Lego, RL Garcia
Publication Date: 2020-04-30

Variant appearance in text: PIK3CA: E542K
PMID: 32365913
View BVdb publication page



Exomes of Ductal Luminal Breast Cancer Patients from Southwest Colombia: Gene Mutational Profile and Related Expression Alterations.

Biomolecules
C Cortes-Urrea, F Bueno-Gutiérrez, M Solarte, M Guevara-Burbano, F Tobar-Tosse, PE Vélez-Varela, JC Bonilla, G Barreto, J Velasco-Medina, PA Moreno, JL Rivas
Publication Date: 2020-04-30

Variant appearance in text: rs121913273
PMID: 32365829
View BVdb publication page



Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.

Angiogenesis
TD Le Cras, J Goines, N Lakes, P Pastura, AM Hammill, DM Adams, E Boscolo
Publication Date: 2020-04-30

Variant appearance in text: PIK3CA: E542K
PMID: 32350708
View BVdb publication page



Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.

Experimental Hematology & Oncology
V Subbiah, EI Dumbrava, Y Jiang, KZ Thein, A Naing, DS Hong, S Fu, SA Piha-Paul, AM Tsimberidou, F Janku, F Meric-Bernstam, R Kurzrock, G Falchook
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32337094
View BVdb publication page



Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.

Breast (Edinburgh, Scotland)
Z Yi, B Liu, X Sun, G Rong, W Wang, H Li, X Guan, L Li, J Zhai, C Li, H Qian, F Ma, B Xu
Publication Date: 2020-04-16

Variant appearance in text: PIK3CA: E542K
PMID: 32335491
View BVdb publication page



IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.

Cancer Medicine
EF Rodriguez, F De Marchi, PM Lokhandwala, D Belchis, R Xian, CD Gocke, JR Eshleman, P Illei, MT Li
Publication Date: 2020-04-25

Variant appearance in text: PIK3CA: E542K
PMID: 32333643
View BVdb publication page



Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Molecular Biology Reports
N Jiang, Q Dai, X Su, J Fu, X Feng, J Peng
Publication Date: 2020-04-24

Variant appearance in text: PIK3CA: E542K
PMID: 32333246
View BVdb publication page



Allelic heterogeneity of Proteus syndrome.

Cold Spring Harbor Molecular Case Studies
A Buser, MJ Lindhurst, HC Kondolf, MR Yourick, KM Keppler-Noreuil, JC Sapp, LG Biesecker
Publication Date: 2020-04-23

Variant appearance in text: PIK3CA: 1624G>A; Glu542Lys
PMID: 32327430
View BVdb publication page



Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients.

Journal Of Advanced Research
A Nassar, M Abouelhoda, O Mansour, SA Loutfy, MM Hafez, M Gomaa, A Bahnassy, AS El-Din Youssef, MM Lotfy, H Ismail, OS Ahmed, AA Abou-Bakr, AN Zekri
Publication Date: 2020-07

Variant appearance in text: PIK3CA: 1624G>A
PMID: 32322420
View BVdb publication page



Molecular Profiles of Brain and Pulmonary Metastatic Disease in Cancer of Unknown Primary.

The Oncologist
BR Bakow, CP Elco, M LeGolvan, D Dizon, TA Ollila
Publication Date: 2020-04-20

Variant appearance in text: PIK3CA: E542K
PMID: 32310333
View BVdb publication page



Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.

Scientific Reports
A El Guerrab, M Bamdad, YJ Bignon, F Penault-Llorca, C Aubel
Publication Date: 2020-04-14

Variant appearance in text: PI3K: E542K
PMID: 32286420
View BVdb publication page



Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.

Breast Cancer Research : Bcr
C Vernieri, F Corti, F Nichetti, F Ligorio, S Manglaviti, E Zattarin, CG Rea, G Capri, GV Bianchi, F de Braud
Publication Date: 2020-04-06

Variant appearance in text: PI3K: E542K
PMID: 32252811
View BVdb publication page



The art of obtaining a high yield of cell-free DNA from urine.

Plos One
E Augustus, K Van Casteren, L Sorber, P van Dam, G Roeyen, M Peeters, A Vorsters, A Wouters, J Raskin, C Rolfo, K Zwaenepoel, P Pauwels
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32251424
View BVdb publication page



Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses.

Cells
G Laetitia, S Sven, J Fabrice
Publication Date: 2020-03-30

Variant appearance in text: PIK3CA: 1624G>A
PMID: 32235612
View BVdb publication page



ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.

Cancers
AM Sieuwerts, MA Inda, M Smid, H van Ooijen, A van de Stolpe, JWM Martens, WFJ Verhaegh
Publication Date: 2020-03-27

Variant appearance in text: PIK3CA: E542K
PMID: 32230714
View BVdb publication page



Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking.

Nature Communications
GD Cresswell, D Nichol, I Spiteri, H Tari, L Zapata, T Heide, CC Maley, L Magnani, G Schiavon, A Ashworth, P Barry, A Sottoriva
Publication Date: 2020-03-27

Variant appearance in text: PIK3CA: E542K
PMID: 32221288
View BVdb publication page



Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel.

Frontiers In Oncology
U Malapelle, F Pepe, P Pisapia, R Sgariglia, M Nacchio, C De Luca, R Lacalamita, S Tommasi, R Pinto, G Palomba, G Palmieri, D Vacirca, M Barberis, I Bottillo, P Grammatico, LR Grillo, V Costa, R Smeraglio, D Bruzzese, G Troncone
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32219061
View BVdb publication page



Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Medical Sciences (Basel, Switzerland)
U Testa, G Castelli, E Pelosi
Publication Date: 2020-03-23

Variant appearance in text: PI3K: E542K
PMID: 32210163
View BVdb publication page



An EGFR-Amplified Cervical Squamous Cell Carcinoma Patient with Pulmonary Metastasis Benefits from Afatinib: A Case Report.

Oncotargets And Therapy
Q Chen, Y Huang, L Shao, H Han-Zhang, F Yang, Y Wang, J Liu, J Gan
Publication Date: 2020

Variant appearance in text: PIK3CA: Glu542Lys
PMID: 32184619
View BVdb publication page



Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.

Plos One
YS Kim, S Sun, JS Yoon, YH Ko, HS Won, JS Kim
Publication Date: 2020

Variant appearance in text: PIK3CA: E542K
PMID: 32176735
View BVdb publication page



Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors.

Science Translational Medicine
JM Schafer, BD Lehmann, PI Gonzalez-Ericsson, CB Marshall, JS Beeler, LN Redman, H Jin, V Sanchez, MC Stubbs, P Scherle, KN Johnson, Q Sheng, JT Roland, JA Bauer, Y Shyr, B Chakravarthy, BC Mobley, SW Hiebert, JM Balko, ME Sanders, PCC Liu, JA Pietenpol
Publication Date: 2020-03-11

Variant appearance in text: PIK3CA: E542K
PMID: 32161105
View BVdb publication page



mTOR pathway somatic variants and the molecular pathogenesis of hemimegalencephaly.

Epilepsia Open
CAB Garcia, SCS Carvalho, X Yang, LL Ball, RD George, KN James, V Stanley, MW Breuss, U Thomé, MV Santos, FP Saggioro, L Neder Serafini, WA Silva, JG Gleeson, HR Machado
Publication Date: 2020-03

Variant appearance in text: PIK3CA: Glu542Lys
PMID: 32140648
View BVdb publication page



XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.

Oncogene
R Tamura, K Yoshihara, H Nakaoka, N Yachida, M Yamaguchi, K Suda, T Ishiguro, K Nishino, H Ichikawa, K Homma, A Kikuchi, Y Ueda, Y Takei, H Fujiwara, T Motoyama, S Okuda, T Wakai, I Inoue, T Enomoto
Publication Date: 2020-03-02

Variant appearance in text: PIK3CA: E542K
PMID: 32115573
View BVdb publication page



Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.

Gastric Cancer : Official Journal Of The International Gastric Cancer Association And The Japanese Gastric Cancer Association
DA Hescheler, PS Plum, T Zander, A Quaas, M Korenkov, A Gassa, M Michel, CJ Bruns, H Alakus
Publication Date: 2020-02-27

Variant appearance in text: PIK3CA: E542K
PMID: 32107691
View BVdb publication page



Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.

Gastroenterology And Hepatology From Bed To Bench
R Ranjbar, S Mohammadpour, A Torshizi Esfahani, S Namazian, M Yaghob-Taleghani, K Baghaei, SA Mortazavi Tabatabaei, L Pasharavesh, E Nazemalhosseini-Mojarad
Publication Date: 2019

Variant appearance in text: PIK3CA: E542K
PMID: 32099598
View BVdb publication page



Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors.

Cancer Cell International
R Oyama, F Kito, M Takahashi, E Hattori, R Noguchi, Y Takai, M Sakumoto, Z Qiao, S Toki, M Sugawara, Y Tanzawa, E Kobayashi, F Nakatani, S Iwata, A Yoshida, A Kawai, T Kondo
Publication Date: 2020

Variant appearance in text: PIK3CA: 1624G>A; E542K
PMID: 32099531
View BVdb publication page



In the literature: February 2020.

Esmo Open
D Roda, V Gambardella, JM Cejalvo, A Cervantes
Publication Date: 2020-02

Variant appearance in text: PI3K: E542K
PMID: 32079625
View BVdb publication page



Comprehensive pharmacogenomic characterization of gastric cancer.

Genome Medicine
JK Sa, JY Hong, IK Lee, JS Kim, MH Sim, HJ Kim, JY An, TS Sohn, JH Lee, JM Bae, S Kim, KM Kim, ST Kim, SH Park, JO Park, HY Lim, WK Kang, NG Her, Y Lee, HJ Cho, YJ Shin, M Kim, H Koo, M Kim, YJ Seo, JY Kim, MG Choi, DH Nam, J Lee
Publication Date: 2020-02-18

Variant appearance in text: PIK3CA: E542K
PMID: 32070411
View BVdb publication page



The paradox of cancer genes in non-malignant conditions: implications for precision medicine.

Genome Medicine
JJ Adashek, S Kato, SM Lippman, R Kurzrock
Publication Date: 2020-02-17

Variant appearance in text: PIK3CA: E542K
PMID: 32066498
View BVdb publication page



Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.

Molecular Oncology
MR Van Bockstal, MC Agahozo, R van Marion, PN Atmodimedjo, HFBM Sleddens, WNM Dinjens, LL Visser, EH Lips, J Wesseling, CHM van Deurzen
Publication Date: 2020-02-14

Variant appearance in text: PIK3CA: 1624G>A; E542K
PMID: 32058674
View BVdb publication page



Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.

Therapeutic Advances In Medical Oncology
QS Chu
Publication Date: 2020

Variant appearance in text: PI3K: E542K
PMID: 32047535
View BVdb publication page



Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

International Journal Of Molecular Sciences
C Tarantelli, A Lupia, A Stathis, F Bertoni
Publication Date: 2020-02-05

Variant appearance in text: PIK3CA: E542K
PMID: 32033478
View BVdb publication page



PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.

Cancer Research And Treatment : Official Journal Of Korean Cancer Association
S Guo, S Loibl, GV Minckwitz, S Darb-Esfahani, B Lederer, C Denkert
Publication Date: 2020-02-04

Variant appearance in text: PIK3CA: E542K
PMID: 32019278
View BVdb publication page



Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy.

Translational Lung Cancer Research
M Tamminga, S de Wit, E Schuuring, W Timens, LWMM Terstappen, TJN Hiltermann, HJM Groen
Publication Date: 2019-12

Variant appearance in text: PIK3CA: E542K
PMID: 32010564
View BVdb publication page



Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC).

Thoracic Cancer
AC Tan
Publication Date: 2020-01-27

Variant appearance in text: PIK3CA: E542K
PMID: 31989769
View BVdb publication page



BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.

Asian Pacific Journal Of Cancer Prevention : Apjcp
E Dirican
Publication Date: 2020-01-01

Variant appearance in text: PIK3CA: E542K
PMID: 31983154
View BVdb publication page



PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies.

Aging
Y Tang, J Li, N Xie, X Yang, L Liu, H Wu, C Tian, Y He, X Wang, Q He, ZY Hu, Q Ouyang
Publication Date: 2020-01-24

Variant appearance in text: PIK3CA: E542K
PMID: 31980592
View BVdb publication page



PIK3CA mutations and downstream effector p-mTOR expression: implication for prognostic factors and therapeutic targets in triple negative breast cancer.

International Journal Of Clinical And Experimental Pathology
J Wang, X Zhu, X Xu, L Guo, G Shen, X Liu, C Chang, B Wang, H Yang, M Wang
Publication Date: 2017

Variant appearance in text: PIK3CA: E542K
PMID: 31966614
View BVdb publication page



Clinicopathologic features and molecular spectrum of spindle cell and sclerosing rhabdomyosarcomas in the head and neck region.

International Journal Of Clinical And Experimental Pathology
Y Wang, J Li, Z Tian, Y Zhu
Publication Date: 2018

Variant appearance in text: PIK3CA: E542K
PMID: 31949721
View BVdb publication page



Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients.

International Journal Of Clinical And Experimental Pathology
R Li, T Tang, T Hui, Z Song, F Li, J Li, J Xu
Publication Date: 2018

Variant appearance in text: PIK3CA: E542K
PMID: 31949629
View BVdb publication page



Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).

Gynecologic Oncology Reports
AD Santin, V Filiaci, S Bellone, ES Ratner, CA Mathews, G Cantuaria, CC Gunderson, T Rutledge, BM Buttin, HA Lankes, M Frumovitz, SN Khleif, WK Huh, MJ Birrer
Publication Date: 2020-02

Variant appearance in text: PIK3CA: E542K
PMID: 31934607
View BVdb publication page



The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

Signal Transduction And Targeted Therapy
M Yuan, LL Huang, JH Chen, J Wu, Q Xu
Publication Date: 2019

Variant appearance in text: PIK3CA: E542K
PMID: 31871778
View BVdb publication page



High-throughput prediction of MHC class I and class II neoantigens with MHCnuggets.

Cancer Immunology Research
XM Shao, R Bhattacharya, J Huang, IKA Sivakumar, C Tokheim, L Zheng, D Hirsch, B Kaminow, A Omdahl, M Bonsack, AB Riemer, VE Velculescu, V Anagnostou, KA Pagel, R Karchin
Publication Date: 2019-12-23

Variant appearance in text: PIK3CA: E542K
PMID: 31871119
View BVdb publication page



Japanese version of cancer genome atlas, JCGA, analyzed by fresh frozen tumors obtained from 5143 cancer patients.

Cancer Science
T Nagashima, K Yamaguchi, K Urakami, Y Shimoda, S Ohnami, K Ohshima, T Tanabe, A Naruoka, F Kamada, M Serizawa, K Hatakeyama, K Matsumura, S Ohnami, K Maruyama, T Mochizuki, M Kusuhara, A Shiomi, Y Ohde, M Terashima, K Uesaka, T Onitsuka, S Nishimura, Y Hirashima, N Hayashi, Y Kiyohara, Y Tsubosa, H Katagiri, M Niwakawa, K Takahashi, H Kashiwagi, M Nakagawa, Y Ishida, T Sugino, M Takahashi, Y Akiyama
Publication Date: 2019-12-21

Variant appearance in text: PIK3CA: E542K
PMID: 31863614
View BVdb publication page



Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.

Plos One
E Papadopoulou, N Tsoulos, K Tsantikidi, V Metaxa-Mariatou, PE Stamou, A Kladi-Skandali, E Kapeni, G Tsaousis, G Pentheroudakis, D Petrakis, DI Lampropoulou, G Aravantinos, I Varthalitis, G Kesisis, I Boukovinas, P Papakotoulas, N Katirtzoglou, E Athanasiadis, F Stavridi, C Christodoulou, A Koumarianou, Y Eralp, G Nasioulas
Publication Date: 2019

Variant appearance in text: PIK3CA: E542K
PMID: 31860648
View BVdb publication page



Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.

Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
M Brandão, R Caparica, D Eiger, E de Azambuja
Publication Date: 2019-12-01

Variant appearance in text: PIK3CA: E542K
PMID: 31859350
View BVdb publication page



Overview of the relevance of PI3K pathway in HR-positive breast cancer.

Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
N Vasan, E Toska, M Scaltriti
Publication Date: 2019-12-01

Variant appearance in text: PIK3CA: E542K
PMID: 31859348
View BVdb publication page



High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.

Molecular Oncology
DT Kruger, MPHM Jansen, IRHM Konings, WM Dercksen, A Jager, J Oulad Hadj, S Sleijfer, JWM Martens, E Boven
Publication Date: 2019-12-16

Variant appearance in text: PIK3CA: E542K
PMID: 31841262
View BVdb publication page



Engineering State-of-the-Art Plasmonic Nanomaterials for SERS-Based Clinical Liquid Biopsy Applications.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
J Wang, KM Koo, Y Wang, M Trau
Publication Date: 2019-12

Variant appearance in text: PIK3CA: E542K
PMID: 31832306
View BVdb publication page



Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.

Cells
C Magaway, E Kim, E Jacinto
Publication Date: 2019-12-06

Variant appearance in text: PIK3CA: E542K
PMID: 31817676
View BVdb publication page



In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines.

Oncology Letters
S Holzhauser, ON Kostopoulou, A Ohmayer, BKA Lange, T Ramqvist, T Andonova, C Bersani, M Wickström, T Dalianis
Publication Date: 2019-12

Variant appearance in text: PIK3CA: E542K
PMID: 31788102
View BVdb publication page



Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance.

World Journal Of Surgical Oncology
N Batta, M Pandey
Publication Date: 2019-11-27

Variant appearance in text: PIK3CA: 1624G>A; Glu542Lys
PMID: 31775759
View BVdb publication page



Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.

Plos One
YJ Chun, JW Choi, MH Hong, D Jung, H Son, EK Cho, YJ Min, SW Kim, K Park, SS Lee, S Kim, HR Kim, BC Cho,
Publication Date: 2019

Variant appearance in text: PIK3CA: E542K
PMID: 31765373
View BVdb publication page



Alternative transcript annotations:

Transcript cDNA Protein Consequence Exon Intron
ENST00000263967.3 c.1624G>A p.Glu542Lys missense_variant 10/21 -
NM_006218.4 c.1624G>A p.Glu542Lys missense_variant 10/21 -